Clinical Indications for Six Commonly Used SSRIs
The six most commonly used SSRIs—fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram—have FDA-approved and evidence-based uses spanning major depressive disorder, anxiety disorders (including OCD, panic disorder, social anxiety, generalized anxiety, and PTSD), eating disorders, and premenstrual dysphoric disorder, with fluoxetine having the broadest FDA approval profile. 1
Individual SSRI Indications
Fluoxetine (Prozac)
FDA-approved indications include:
- Major depressive disorder (including in children/adolescents ≥8 years—the only SSRI with this pediatric depression approval)
- Obsessive-compulsive disorder
- Bulimia nervosa
- Premenstrual dysphoric disorder
- Panic disorder
- Bipolar disorder (in combination with olanzapine) 1
Paroxetine (including controlled-release formulation)
FDA-approved indications include:
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Social anxiety disorder
- Premenstrual dysphoric disorder
- Generalized anxiety disorder
- Posttraumatic stress disorder 1
Important caveat: Paroxetine carries increased risk of suicidal thinking/behavior compared to other SSRIs and has significant discontinuation syndrome risk 2
Sertraline, Fluvoxamine, Citalopram, and Escitalopram
While these SSRIs are marketed in the United States and have demonstrated efficacy for anxiety disorders (social anxiety, generalized anxiety, separation anxiety, panic disorder) in children and adolescents aged 6-18 years, no specific SSRIs have FDA approval for anxiety disorder indications 2
Evidence-Based Uses Across the SSRI Class
Anxiety Disorders
SSRIs as a class demonstrate moderate to high strength of evidence for:
- Social anxiety disorder
- Generalized anxiety disorder
- Separation anxiety disorder
- Panic disorder 2
Clinical response timeline: Statistically significant improvement occurs within 2 weeks, clinically significant improvement by week 6, and maximal improvement by week 12 or later 2
Obsessive-Compulsive Disorder
SSRIs are first-line pharmacological treatment for OCD based on efficacy, tolerability, safety, and absence of abuse potential 3
Key prescribing difference: Higher doses are required for OCD than for depression or other anxiety disorders (fluoxetine 60-80 mg, paroxetine 60 mg), though higher doses increase dropout rates due to adverse effects 1, 3
Treatment duration: Minimum 8-12 weeks to determine efficacy; maintenance therapy should continue 12-24 months after remission, though many patients require longer treatment due to relapse risk 3
Depression
All six SSRIs demonstrate comparable efficacy for major depressive disorder in adults, with no clinically significant differences in effectiveness between individual agents 4, 5
Other Established Indications
Evidence supports SSRI use for:
- Dysthymia
- Atypical depression
- Premenstrual tension
- Eating disorders (particularly bulimia for fluoxetine)
- Chronic pain syndromes 1, 6, 7
Critical Prescribing Considerations
Drug-Specific Warnings
Citalopram: Maximum dose 40 mg/day due to QT prolongation risk (Torsade de Pointes, ventricular tachycardia, sudden death); avoid in long QT syndrome 2
Fluvoxamine: Greater potential for drug-drug interactions via multiple CYP450 isoenzymes (CYP1A2, CYP2C19, CYP2C9, CYP3A4, CYP2D6); may require twice-daily dosing 2
Paroxetine: Highest risk for discontinuation syndrome and increased suicidal thinking/behavior compared to other SSRIs 2
Fluoxetine, Paroxetine, Sertraline: Interact with drugs metabolized by CYP2D6 2
Citalopram/Escitalopram: Least effect on CYP450 isoenzymes, therefore lowest propensity for drug interactions 2
Universal SSRI Warnings
- Black box warning: Suicidal thinking and behavior through age 24 years (number needed to harm = 143 vs. number needed to treat = 3) 2
- Serotonin syndrome risk: Contraindicated with MAOIs; exercise caution when combining with other serotonergic drugs 2
- Discontinuation syndrome: Particularly with shorter-acting agents (paroxetine > fluvoxamine > sertraline) 2
Pharmacokinetic Differences
Fluoxetine: Longest half-life due to active metabolite; permits single daily dosing; requires 3-4 week intervals between dose adjustments 2
Sertraline: May require twice-daily dosing at low doses; 1-2 week intervals between dose adjustments 2
Fluvoxamine: Requires twice-daily dosing at any dose 2
Selection Algorithm
Choose based on:
- FDA-approved indication (if applicable—e.g., fluoxetine for pediatric depression, bulimia)
- Drug interaction profile (citalopram/escitalopram preferred when multiple medications present)
- Cardiac risk factors (avoid citalopram if QT prolongation risk)
- Prior discontinuation syndrome (avoid paroxetine, fluvoxamine, sertraline)
- Dosing convenience (fluoxetine for once-daily dosing)
- Cost and formulary considerations 2